(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Put resources into Lab Precious stones - 2Israeli naval intelligence reduces Iranian threat to Strait of Hormuz
- 3The most effective method to Distinguish the Best Material Organization in Your Space
- 4A 'rampaging lion' nebula roars to life in a stunning deep-space photo
- 5Step by step instructions to Explore Assessment Ramifications of Disc Rates
- Desired Travel Objections Worldwide: Where to Go Straightaway
- Beating Scholastic Difficulties: Understudy Examples of overcoming adversity
- Mobility exercises are an important part of fitness as we age. Here are some tips
- Most loved Seared Chicken: Which Chain Rules?
- ‘Inoculation’ helps people spot political deepfakes, study finds
- Congolese rape survivors search in vain for medicine after USAID cuts
- UAE-backed Yemeni Southern Transitional Council denies disbandment rumors
- CDC pauses dozens of types of lab testing during evaluation and in wake of downsizing
- Trump administration plan to reduce access to some student loans angers nurses, health care groups
